Ocular Therapeutix Inc

0.00 (0.00%)
Products, Regulatory

Ocular Therapeutix Inc Intends To Initiate Phase 2 Clinical Trial For Otx-Tki In Australia In Mid-2021

Published: 10/13/2020 21:55 GMT
Ocular Therapeutix Inc (OCUL) - Ocular Therapeutix Inc - Intend to Initiate a Phase 2 Clinical Trial for Otx-tki in Australia in Mid-2021.
Ocular Therapeutix - Uspto Recently Allowed a Patent Application Filed by a Third Party Related to Intracanalicular Inserts Containing Dexamethasone.
Ocular Therapeutix Inc - Come to an Agreement With FDA to Conduct a Retrospective Study Looking at Sites With Access to Resure Versus Those Without Access.
Ocular, on Resure Sealant, Says Agreement With FDA is to Conduct Retrospective Study Using American Academy of Ophthalmology’s Iris Registry Data Base.